Mehnaz Zafar Ali
Research Subjects
Mehnaz Zafar Ali has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Abdel Rahman Elrashedy
Johnson and Johnson Middle East FZ-LLC, Dubai Healthcare City, Dubai, United Arab Emirates
1 shared publication Amr Nasrallah
Johnson and Johnson Middle East FZ-LLC, Dubai Healthcare City, Dubai, United Arab Emirates
1 shared publication- Faisal A. Nawaz
Al Amal Psychiatric Hospital
1 shared publication - Jessie Joseph
Rashid Hospital
1 shared publication - Lana Kanj
Mohammed Bin Rashid University of Medicine and Health Sciences
1 shared publication - Lorenzo Pradelli
AdRes HE&OR, Turin, Italy
1 shared publication
Latest Publications
- 17 August 2026
- Published by SAGE Publications in The International Journal of Psychiatry in Medicine
Antidepressant-Induced Rapid Eye Movement Behavioral Sleep Disorder (RBD): A Scoping Review
Objective: Rapid Eye Movement sleep behavior disorder (RBD) is a parasomnia characterised by the loss of normal skeletal muscle atonia during REM sleep, leading to the enactment of dreams through complex motor behaviors such as talking, shouting, or violent movements that may result in injury. Emerging evidence suggests that antidepressants may be associated with RBD. This study reviewed the existing literature on the demographic and clinical features of patients with REM sleep behavior disorder (RBD) taking antidepressants, as well as the reported associations between antidepressant use and RBD. Methods: A comprehensive search strategy was implemented using the PRISMA for Scoping Reviews framework. Eligible study designs included cohort, cross-sectional, observational, randomised controlled trials, and case reports. Searches were conducted on Science Direct and PubMed for studies published between 1957 and 2025. Search terms included “REM sleep behavior disorder,” “dream enactment behavior,” “antidepressants,” “SSRIs,” “SNRIs,” and “TCAs.” The scoping review protocol was pre-registered on the Open Science Framework. Results: Title and abstract screening yielded 650 studies, with 16 studies meeting the inclusion criteria after full-text review. Data from 500 patients indicated a male predominance (70.2%), with a mean age of 53.9 years. Depression was the most common comorbidity (8 studies). SSRIs were most frequently associated with RBD (in 8 studies), followed by SNRIs (6 studies) and TCAs (6 studies). Conclusion: Antidepressant-associated RBD is an emerging clinical concern requiring greater recognition and monitoring to enhance treatment outcomes. A clearer understanding of these relationships will ultimately improve risk stratification, patient counseling, and individualized treatment strategies in clinical settings.
- 17 August 2026
- Published by SAGE Publications in The International Journal of Psychiatry in Medicine
Antidepressant-Induced Rapid Eye Movement Behavioral Sleep Disorder (RBD): A Scoping Review
Objective: Rapid Eye Movement sleep behavior disorder (RBD) is a parasomnia characterised by the loss of normal skeletal muscle atonia during REM sleep, leading to the enactment of dreams through complex motor behaviors such as talking, shouting, or violent movements that may result in injury. Emerging evidence suggests that antidepressants may be associated with RBD. This study reviewed the existing literature on the demographic and clinical features of patients with REM sleep behavior disorder (RBD) taking antidepressants, as well as the reported associations between antidepressant use and RBD. Methods: A comprehensive search strategy was implemented using the PRISMA for Scoping Reviews framework. Eligible study designs included cohort, cross-sectional, observational, randomised controlled trials, and case reports. Searches were conducted on Science Direct and PubMed for studies published between 1957 and 2025. Search terms included “REM sleep behavior disorder,” “dream enactment behavior,” “antidepressants,” “SSRIs,” “SNRIs,” and “TCAs.” The scoping review protocol was pre-registered on the Open Science Framework. Results: Title and abstract screening yielded 650 studies, with 16 studies meeting the inclusion criteria after full-text review. Data from 500 patients indicated a male predominance (70.2%), with a mean age of 53.9 years. Depression was the most common comorbidity (8 studies). SSRIs were most frequently associated with RBD (in 8 studies), followed by SNRIs (6 studies) and TCAs (6 studies). Conclusion: Antidepressant-associated RBD is an emerging clinical concern requiring greater recognition and monitoring to enhance treatment outcomes. A clearer understanding of these relationships will ultimately improve risk stratification, patient counseling, and individualized treatment strategies in clinical settings.
- Open Access
- 2 March 2026
- Published by Seed SRL in Farmeconomia. Health economics and therapeutic pathways
- Vol. 27 (1) , 45-54
Clinical and Economic Benefits of Long-Acting Injectable Paliperidone in Schizophrenia: A UAE-Based Modeling Study
INTRODUCTION: Poor adherence to oral antipsychotic (OAP) therapy is a major driver of relapse in patients with schizophrenia, as only 50% or fewer patients are adherent to OAP during the first year, leading to suboptimal clinical outcomes and substantial healthcare costs. Long-acting injectable (LAI) antipsychotics enhance treatment continuity and sustained drug exposure, with real-world data showing improved effectiveness as dosing intervals lengthen due to better adherence. We evaluate the clinical and economic consequences, in the United Arab Emirates (UAE) healthcare setting, of switching patients with schizophrenia from OAPs to paliperidone LAIs with different dosing intervals, including semi-annual formulations (PP6M).METHODS: Hazard ratios (HRs) for relapse were derived from an updated systematic review and incorporated into a Bayesian hierarchical model capturing the combined effects of route of administration and dosing frequency. Model outputs were used to populate a cost-consequence model developed from the UAE healthcare third-party payer perspective. Only direct medical costs were considered with hospitalization used as a proxy for relapse. Analyses were conducted over 1- and 5-year time horizons.RESULTS: Over the 1-year horizon, the total budget per patient decreased by approximately 8%, 26%, and 50% following switches from OAP to paliperidone palmitate 1-month, 3-month, and 6-month formulations respectively. This corresponded to an estimated saving of ~20,000 AED per patient per year with PP6M which was associated with the lowest predicted relapse rates. Although longer-acting LAIs were associated with higher pharmaceutical expenditure per injection, reductions in relapse-related hospitalizations generated budget saving that exceeded incremental drug costs. CONCLUSIONS: In the UAE context, transitioning patients with schizophrenia from OAPs to paliperidone LAIs, including PP6M, may improve disease control and lead to favorable economic outcomes. Improved adherence translates into clinically meaningful reductions in relapse, with overall cost savings driven by avoided hospitalizations, supporting broader adoption of LAI strategies.
- 2 March 2026
- Published by Seed SRL in Farmeconomia. Health economics and therapeutic pathways
- Vol. 27 (1) , 45-54
Open AccessClinical and Economic Benefits of Long-Acting Injectable Paliperidone in Schizophrenia: A UAE-Based Modeling Study
INTRODUCTION: Poor adherence to oral antipsychotic (OAP) therapy is a major driver of relapse in patients with schizophrenia, as only 50% or fewer patients are adherent to OAP during the first year, leading to suboptimal clinical outcomes and substantial healthcare costs. Long-acting injectable (LAI) antipsychotics enhance treatment continuity and sustained drug exposure, with real-world data showing improved effectiveness as dosing intervals lengthen due to better adherence. We evaluate the clinical and economic consequences, in the United Arab Emirates (UAE) healthcare setting, of switching patients with schizophrenia from OAPs to paliperidone LAIs with different dosing intervals, including semi-annual formulations (PP6M).METHODS: Hazard ratios (HRs) for relapse were derived from an updated systematic review and incorporated into a Bayesian hierarchical model capturing the combined effects of route of administration and dosing frequency. Model outputs were used to populate a cost-consequence model developed from the UAE healthcare third-party payer perspective. Only direct medical costs were considered with hospitalization used as a proxy for relapse. Analyses were conducted over 1- and 5-year time horizons.RESULTS: Over the 1-year horizon, the total budget per patient decreased by approximately 8%, 26%, and 50% following switches from OAP to paliperidone palmitate 1-month, 3-month, and 6-month formulations respectively. This corresponded to an estimated saving of ~20,000 AED per patient per year with PP6M which was associated with the lowest predicted relapse rates. Although longer-acting LAIs were associated with higher pharmaceutical expenditure per injection, reductions in relapse-related hospitalizations generated budget saving that exceeded incremental drug costs. CONCLUSIONS: In the UAE context, transitioning patients with schizophrenia from OAPs to paliperidone LAIs, including PP6M, may improve disease control and lead to favorable economic outcomes. Improved adherence translates into clinically meaningful reductions in relapse, with overall cost savings driven by avoided hospitalizations, supporting broader adoption of LAI strategies.